PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsadenocarcinoma
MeSH D000230 - adenocarcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002277:Carcinoma
18 Companies
3 Drugs
$
Success rate
D000230: 
Adenocarcinoma
24 Companies
3 Drugs
$
Success rate
D000077192:Adenocarcinoma of lung
0 Companies
0 Drugs
Success rate
D000231:Papillary adenocarcinoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
2 Companies
2 Drugs
$
Success rate
D002285:Intraductal carcinoma noninfiltrating
0 Companies
0 Drugs
Success rate
D002288:Mucinous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002292:Renal cell carcinoma
55 Companies
25 Drugs
$
Success rate
D002293:Scirrhous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002822:Choriocarcinoma
36 Companies
5 Drugs
$
Success rate
D003528:Adenoid cystic carcinoma
0 Companies
0 Drugs
Success rate
D003536:Cystadenocarcinoma
0 Companies
0 Drugs
Success rate
D006528:Hepatocellular carcinoma
13 Companies
10 Drugs
$
Success rate
D010145:Extramammary paget disease
45 Companies
10 Drugs
$
Success rate
D011648:Ovine pulmonary adenomatosis
0 Companies
0 Drugs
Success rate
D018262:Clear cell adenocarcinoma
0 Companies
0 Drugs
Success rate
D018263:Follicular adenocarcinoma
0 Companies
0 Drugs
Success rate
D018266:Sebaceous adenocarcinoma
0 Companies
0 Drugs
Success rate
D018267:Acinar cell carcinoma
0 Companies
0 Drugs
Success rate
D018268:Adrenocortical carcinoma
1 Company
1 Drug
$
Success rate
D018269:Endometrioid carcinoma
0 Companies
0 Drugs
Success rate
D018273:Islet cell carcinoma
7 Companies
2 Drugs
$
Success rate
D018275:Lobular carcinoma
0 Companies
0 Drugs
Success rate
D018277:Mucoepidermoid carcinoma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
D018279:Signet ring cell carcinoma
0 Companies
0 Drugs
Success rate
D018280:Skin appendage carcinoma
0 Companies
0 Drugs
Success rate
D018281:Cholangiocarcinoma
3 Companies
3 Drugs
$
Success rate
D044584:Ductal carcinoma
0 Companies
0 Drugs
Success rate
D057090:Eccrine porocarcinoma
0 Companies
0 Drugs
Success rate
D065311:Adenocarcinoma in situ
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaDocetaxel Docetaxel Teva  2010-01-26   
MylanDocetaxel Docetaxel Mylan  2012-01-31   
SanofiDocetaxel Taxotere  1995-11-27   
HospiraMitomycin Mitomycin  1995-11-29   
Bristol Myers SquibbMitomycin Mutamycin  1982-01-01   
Accord HealthcareDocetaxel Docetaxel Accord  2012-05-22   
Mitomycin Mitomycin  1998-04-30   
Hikma PharmaceuticalsMitomycin Mitomycin  1995-04-19   
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
84%
102/122
Phase 2
28%
55/197
Phase 3
16%
12/75
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Docetaxel
Mylan
Docetaxel
Sanofi
Docetaxel,
Transplatin,
Antithrombin iii,
Ziv-aflibercept,
Tusamitamab ravtansine,
Aglatimagene besadenovec,
Lenograstim,
Ademetionine,
Sulodexide,
Doconexent,
Fludeoxyglucose f-18,
Aspartame,
Bevifimod,
Telbermin,
Retinol,
Sar-408701,
Folinoral,
Arm1,
For46,
Bolus,
Capox,
Docetaxol,
Taxane,
Adt
Bristol Myers Squibb
Mitomycin,
Rucaparib,
Transplatin,
Rucaparib camsylate,
Albumin,
Entinostat,
Aglatimagene besadenovec,
Rigosertib,
Brivanib alaninate,
Ademetionine,
EFINEPTAKIN ALFA,
SOTIGALIMAB,
Sodium chloride,
APRICOXIB,
Bevifimod,
Farletuzumab,
Nepidermin,
Telbermin,
URELUMAB,
Vilobelimab,
Retinol,
Gvax,
Q2w,
Hcq,
Folinoral,
Sbrt,
Tmz,
Arm1,
Bsc,
Gemcis,
Pcd,
Bolus,
Docetaxol,
Enantone,
Fluoropyrimidine,
Hidroxicloroquina,
Adt,
Sominex
Fresenius Kabi
Thiotepa
Astex Pharmaceuticals
Mitomycin
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use